PT Kalbe Farma Tbk. PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk.

KLBF

Rank in Stocks #6024
PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its... PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its subsidiaries, focuses on the development, manufacturing, and commercialization of pharmaceutical products across Indonesia. Its operations are structured into four primary divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. The company's diverse portfolio encompasses generic, branded, and licensed medications, including well-known names like Brainact, Cefspan, and Mycoral, which are supplied to hospitals, pharmacies, and various drugstores. Beyond prescription drugs, it offers non-prescription medicines, a range of energy and ready-to-drink beverages, dietary supplements, and other preventive health solutions. Kalbe Farma also produces specialized nutritional products tailored for all demographics, from infants to seniors, including expectant mothers and individuals with specific medical dietary needs. The firm extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence assessments, and analytical testing. Additionally, it provides animal health products and operates its own healthcare facilities, the Mitrasana Clinics. Its broad scope of activities further includes health screening, acting as an agent for biotechnology products, and the distribution of consumer items, medical devices, and cosmetics. The company also trades in medical and laboratory equipment and supplies, raw materials for pharmaceuticals, and consumables for hemodialysis therapy, in addition to offering advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.
Share Price
$0.04249975
Last synced: 2026-11-16
Market Cap
$1.92B
Change (1 day)
1.99%
Change (1 year)
-41.90%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for PT Kalbe Farma Tbk. (KLBF)
EPS as of September 2026 TTM: $0.00
According to PT Kalbe Farma Tbk.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, equal to its 2024 EPS of 0.00.
EPS history for PT Kalbe Farma Tbk. from 2005 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) 0.00 11.63%
2025 0.00 11.63%
2024 0.00 10.26%
2023 0.00 -17.02%
2022 0.00 -2.08%
2021 0.00 14.29%
2020 0.00 10.53%
2019 0.00 5.56%
2018 0.00 -5.26%
2017 0.00 5.56%
2016 0.00 16.13%
2015 0.00 -11.43%
2014 0.00 2.94%
2013 0.00 -10.53%
2012 0.00 8.57%
2011 0.00 16.67%
2010 0.00 42.86%
2009 0.00 61.54%
2008 0.00 -13.33%
2007 0.00 0.00%
2006 0.00 15.38%
2005 0.00 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$30.89 671,421.74%
US
$6.60 143,378.26%
US
$5.83 126,639.13%
US
$18.31 398,021.74%
CH
$0.99 21,421.74%
US

Questions about PT Kalbe Farma Tbk.'s earnings per share (EPS)

What is PT Kalbe Farma Tbk.'s earnings per share (EPS)?

PT Kalbe Farma Tbk.'s earnings per share (EPS) over the last twelve months is $0.00, as of Sep 2026.

What was PT Kalbe Farma Tbk.'s earnings per share (EPS) in 2025?

In 2025, PT Kalbe Farma Tbk.'s earnings per share (EPS) was 0.00, compared with 0.00 in 2024.

How has PT Kalbe Farma Tbk.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, PT Kalbe Farma Tbk.'s earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2025 (0.00).

How does PT Kalbe Farma Tbk.'s earnings per share (EPS) compare with similar companies?

PT Kalbe Farma Tbk.'s earnings per share (EPS) ($0.00) is lower than that of all 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.